PI3K

[Cancer Immunology Immunotherapy] Scientists investigated in vitro, ex vivo and in vivo effects of a novel chemical compound targeting HCK inhibition, in combination with the most used drugs for the treatment of myelodysplastic syndrome and de novo acute myeloid leukemia, 5-Azacytidine and Cytarabine.

[Cell Death & Disease] The authors showed 2nd generation hexameric TRAIL-receptor-agonist IZI1551 to effectively induce apoptosis in malignant melanoma cells irrespective of the intrinsic BRAF/NRAS mutation status.

[Cell Death Discovery] Scientists investigated the effects of hCAP18/LL-37 on hepatocellular carcinoma (HCC) in vitro and in vivo. Results showed that hCAP18/LL-37 overexpression significantly promoted the proliferation of cultured HCC cells and the growth of PLC/PRF-5 xenograft tumor.

[Nature Communications] Scientists found that intermittent but not daily dosing of a PI3Kα/β/δ inhibitor, BAY1082439, on Pten-null prostate cancer models could overcome immune checkpoint therapy resistance and unleash CD8+ T cell-dependent anti-tumor immunity in vivo.

[Clinical and Translational Oncology] Researchers aimed to investigate the role and underlying molecule mechanism of very-long-chain acyl-CoA dehydrogenase (VLCAD) in the pathological process of hepatocellular carcinoma.

[Nature Communications] Researchers demonstrated that a large subset of TNBC expressed significant levels of MAPK4, and this expression was critical for driving AKT activation independent of PI3K and promoting TNBC cell and xenograft growth.